Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ono Aims at Sales of ¥10 Bil. for Emend
December 6, 2010
- Need for Closer Cooperation Reconfirmed at 4th THMM
December 6, 2010
- Major Dispensing Pharmacy Chains Introduce More Automatic Dispensing Systems
December 6, 2010
- EPS: Sales Up 25% Driven by CSO Business
December 6, 2010
- Efficacy Not Confirmed for NV1FGF in PIII: AHA
December 6, 2010
- Use of Points for Out-of-Pocket Payments Unacceptable: JPA
December 6, 2010
- Safety, Efficacy of Anacetrapib Confirmed in PIII: AHA
December 6, 2010
- Novartis, sanofi-aventis to Copromote Equa
December 6, 2010
- BMS, Pfizer Discontinue Apixaban Development for ACS
December 6, 2010
- Shionogi Leads IP Assets Ranking Followed by Kyowa Kirin
December 6, 2010
- Kyowa Kirin to Present KW-0761 Results at ASH
December 6, 2010
- Janssen Resumes Supply of Velcade
December 6, 2010
- BI Publishes Dabigatran Sub-Group Analysis
December 6, 2010
- Popular Name Made Legal Name: InCROM
December 6, 2010
- OncoTherapy Starts Clinical Trial for Gastric Tumor Vaccine
December 6, 2010
- NHI Pricing Recommended for Xyzal, Byetta
December 6, 2010
- PAFSC Withholds Recommending Switch OTC Version of Epadel
December 6, 2010
- Oral Ketotifen Products Should Remain in Class 1: JPA
November 29, 2010
- Bristol-Myers Required to Develop Largest Number of Unapproved Drugs/Indications
November 29, 2010
- 64 Amaryl Generics from 28 Companies Listed
November 29, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…